New oral drug ICM20 tested for safety in chagas patients
NCT ID NCT05523596
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 28 times
Summary
This early-stage study tested the safety of an oral drug called ICM20 in 13 adults with Chagas disease, a parasitic infection. Participants took the drug for up to 60 days while doctors monitored for side effects. The goal was to see if ICM20 is safe enough to study further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Culmore Clinic
Falls Church, Virginia, 22044, United States
-
Parkway Medical
Glen Burnie, Maryland, 21061, United States
Conditions
Explore the condition pages connected to this study.